9 tips on selecting oral anticoagulants

  1. START anticoagulants based on a systematic assessment of a person’s potential risk of thromboembolism using the CHADS2 score.1,2
  2. Risk factors for bleeding should be identified, as well as patients who need increased clinical monitoring (those with three or more risk factors) using the HAS-BLED tool.3 
  3. People at high risk of bleeding are not precluded from anticoagulation but regular clinical review is recommended.4
  4. Treat correctable risk factors for bleeding, and consider a Home Medicines Review5 for people prescribed anticoagulant therapy. 
  5. Twice-annual reviews may benefit patients with three or more risk factors for bleeding.6 
  6. Dabigatran (Pradaxa), apixaban (Eliquis) and rivaroxaban (Xarelto) are newer anticoagulant medicines that have been subsidised by the PBS since 2013 for the prevention of stroke and systemic embolism in patients with non